MarketCap
Facebook
X
Telegram
Chembio Diagnostics Net Income | CEMI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.3 M | -33.9 M | -25.5 M | -13.7 M | -7.87 M | -6.37 M | -13.3 M | -2.4 M | -1.14 M | 531 K | 941 K | 6.21 M | 2.51 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | -33.9 M | -9.02 M |
Quarterly Net Income Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -6.7 M | -6.95 M | -8.79 M | - | -6.37 M | -9.06 M | -4.5 M | - | -5.54 M | -7.84 M | -5 M | - | -3.78 M | -3.19 M | -2.82 M | - | -2.31 M | -1.73 M | -652 K | -2 M | -585 K | -2.17 M | -1.62 M | -2.56 M | -2.14 M | -8.35 M | -304 K | -649 K | -437 K | -664 K | -647 K | - | -271 K | -146 K | -225 K | - | 717 K | -241 K | 317 K | - | -292 K | 309 K | 433 K | - | 476 K | 195 M | -142 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | -9.06 M | 2.52 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Centogene N.V.
CNTG
|
-35.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
NeoGenomics
NEO
|
-108 M | $ 15.29 | -3.72 % | $ 1.96 B | USA |
 |
Neogen Corporation
NEOG
|
-7.9 M | $ 12.04 | 4.42 % | $ 2.62 B | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Natera
NTRA
|
-208 M | $ 267.76 | -0.7 % | $ 36.6 B | USA |
 |
OPKO Health
OPK
|
-226 B | $ 1.32 | -1.12 % | $ 991 M | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 416.3 | 2.6 % | $ 29.2 B |  Schweiz |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 26.3 | -0.53 % | $ 24.9 B |  Niderland |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 12.66 | 3.09 % | $ 1.13 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Quidel Corporation
QDEL
|
810 M | $ 16.77 | 1.21 % | $ 706 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Celcuity
CELC
|
-177 M | $ 86.38 | -1.44 % | $ 4.04 B | USA |
 |
Neuronetics
STIM
|
-39 M | $ 1.98 | 0.51 % | $ 131 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-12 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-811 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 43.71 | 14.72 % | $ 2.33 B | USA |
 |
Waters Corporation
WAT
|
643 M | $ 377.31 | -0.79 % | $ 22.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 163.57 | -1.19 % | $ 12.8 B |  Irlanda |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Exagen
XGN
|
-20 M | $ 4.53 | -3.0 % | $ 97.7 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 233.01 | -0.58 % | $ 25.9 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
-4.97 M | $ 1.49 | -6.28 % | $ 3.42 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
-13.8 M | - | -2.3 % | $ 19.4 M | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 7.27 | -1.76 % | $ 29 M | Israel |
 |
OpGen
OPGN
|
23.6 M | - | -16.95 % | $ 1.54 M | USA |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 3.42 | -3.93 % | $ 111 K | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 1.44 | -7.69 % | $ 1.92 M | USA |
 |
DexCom
DXCM
|
836 M | $ 83.45 | 11.95 % | $ 32.6 B | USA |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
-50.1 M | - | -39.35 % | $ 313 K | USA |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |